MedPath

Acetylcysteine

Generic Name
Acetylcysteine
Brand Names
Acetadote
Drug Type
Small Molecule
Chemical Formula
C5H9NO3S
CAS Number
616-91-1
Unique Ingredient Identifier
WYQ7N0BPYC
Background

Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.

Acetylcysteine was granted FDA approval on 14 September 1963.

Indication

Acetylcysteine is indicated for mucolytic therapy and in the management of acetaminophen overdose.

Associated Conditions
Acetaminophen Overdose, Chronic Rhinitis, Corneal Diseases, Corneal ulceration, Crusting Rhinitis, Keratopathy, Rhinitis, Sinusitis, Vasomotor Rhinitis, Acute Rhinitis, Subacute Rhinitis
Associated Therapies
Airway secretion clearance therapy

Comparison of Different Mucoactive Agents for the Care of the Intubated Patient in a Surgical Trauma Intensive Care Unit

Not Applicable
Completed
Conditions
Mucus Obstruction
Intubation
First Posted Date
2005-08-18
Last Posted Date
2009-06-23
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
260
Registration Number
NCT00131521
Locations
🇺🇸

Univesity Hospital, San Antonio, Texas, United States

An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac Surgery

Phase 2
Completed
Conditions
Kidney Failure, Acute
Kidney Failure, Chronic
Cardiac Surgical Procedures
Interventions
First Posted Date
2005-07-21
Last Posted Date
2014-11-07
Lead Sponsor
Linda F. Barr, M.D.
Target Recruit Count
80
Registration Number
NCT00122018

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

Phase 2
Completed
Conditions
Melanoma (Skin)
First Posted Date
2003-04-25
Last Posted Date
2013-06-25
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
80
Registration Number
NCT00003346
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen

Phase 3
Completed
Conditions
Acute Liver Failure
Interventions
First Posted Date
1999-10-19
Last Posted Date
2017-10-13
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
173
Registration Number
NCT00004467
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

University of Washington Medical Center, Seattle, Washington, United States

🇺🇸

University of California Los Angeles, Los Angeles, California, United States

and more 20 locations
© Copyright 2025. All Rights Reserved by MedPath